Journal September 19, 2026 4 min read

Common misconceptions about resolution of inflammation

Resolution of inflammation is an active, drug-targetable process, not passive decay. This page examines what the evidence shows about follistatin, SPMs, doxycycline, and other research compounds in models of inflammatory

peptides-pro Editorial

What resolution of inflammation actually is

Resolution of inflammation is the active, programmed termination of an inflammatory response, distinct from simple suppression or passive decay. It is driven by endogenous mediators and cellular reprogramming, and it is studied as a drug-targetable process rather than an absence of inflammation. The formal term is resolution of inflammation; related terms include catabasis and inflammatory resolution. It is not a compound class but a biological process, and it has no single sequence, formula, or molecular weight. The evidence below centres on the TGF-β superfamily and its regulation by follistatin, on specialised pro-resolving mediators (SPMs), and on matrix metalloproteinase (MMP) inhibition as a host-directed strategy.

Misconception 1: resolution is passive. Misconception 2: it is the same as immunosuppression. Misconception 3: any anti-inflammatory drug promotes it. The studies below test these assumptions in specific models and populations.

Research Studies

Follistatin and atherosclerosis in mice

Follistatin (FST) binds and neutralises members of the TGF-β superfamily, regulating skeletal muscle, adipose, and bone homeostasis. In the Hybrid Mouse Diversity Panel (HMDP), transcriptomic and metabolomic analyses showed that Fst expression was negatively correlated with aortic lesion area. FST also promoted adipose browning and improved plasma lipid profiles in mice. This work is animal-only [1].

Follistatin and arginine metabolism in adipose tissue

The same study linked FST to activation of arginine metabolism alongside adipose browning. These mechanistic findings were generated in mouse models and cell systems, not in humans [1].

Oral SPM supplementation and vascular ageing in obese hypertensive patients

A registered clinical trial is testing whether oral SPM supplementation affects inflammation-induced vascular ageing in obese hypertensive patients. The rationale is that residual cardiovascular risk persists despite optimal treatment of risk factors, and that vascular lesions are largely driven by inflammation. This is a trial in a specific patient population; results are not yet reported here [2].

Adjunctive doxycycline and MMP inhibition in CNS tuberculosis

In central nervous system tuberculosis (CNS-TB), the activity of pathogenic host MMPs is unopposed to tissue inhibitors of metalloproteinases (TIMPs), producing a matrix-degrading phenotype. In a murine CNS-TB model, adjunctive MMP inhibition with doxycycline was studied. The clinical trial is in patients with CNS-TB, where standard-of-care mortality remains 30–50% even in tertiary centres [3].

Adjunctive doxycycline and pulmonary tuberculosis outcomes

A Phase 2b double-blind randomised-controlled trial found that adjunctive doxycycline therapy was safe, accelerated resolution of inflammation, suppressed tissue-damaging enzyme activity, and decreased pulmonary cavity volume. A Phase III trial is now planned to test whether adjunctive doxycycline reduces pulmonary impairment after tuberculosis (PIAT) and improves cardiovascular outcomes in patients with pulmonary TB [4].

Dental pulp stem cells and plaque biofilm infections

A structured narrative review (2000–2025) synthesised evidence on the antimicrobial, immunomodulatory, and regenerative properties of dental pulp stem cells (DPSCs) in plaque-induced gingivitis and oral biofilm infections. This is a review of in vitro and preclinical literature, not a clinical trial [5].

Recombinant Klotho and sterile inflammation after haemorrhagic shock

Recombinant Klotho protein has been studied for its anti-inflammatory, antiapoptotic, and antioxidative properties in haemorrhagic shock, a condition of systemic hypoperfusion that induces inflammatory responses and can lead to multiple organ failure. This work is preclinical [6].

Comparing model systems for resolution research

Compound/Intervention	Model or population	Key reported finding
Follistatin	Mice (HMDP)	Fst negatively correlated with aortic lesion area; adipose browning and improved lipid profile [1]
Oral SPMs	Obese hypertensive patients	Trial testing vascular ageing; results not reported here [2]
Doxycycline	CNS-TB patients; murine model	MMP inhibition studied; clinical trial in progress [3]
Doxycycline	Pulmonary TB patients	Phase 2b: safe, accelerated resolution, reduced cavity volume; Phase III planned [4]
DPSCs	In vitro/preclinical review	Antimicrobial and immunomodulatory properties reported [5]
Recombinant Klotho	Preclinical haemorrhagic shock	Mitigated sterile inflammation [6]

If you are reading this for personal health reasons

The materials described here are sold for laboratory research only. We do not provide dosing, medical guidance, or recommendations for human use. Anyone considering a compound for themselves should speak to a licensed clinician.